An observational study in Myelofibrosis (MF), sponsored by Swedish Orphan Biovitrum. Recruiting at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Swedish Orphan Biovitrum · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 453 studies in Primary Myelofibrosis with a site in United States — 69 open to participants now, 104 under way, 12 of them phase 3. Primary Myelofibrosis · United States.
Among the 453 studies in Primary Myelofibrosis with a site in United States, this one is the 23rd largest by planned enrollment of the 35 observational ones that give a count, is one of 17 that started in 2026, is one of 35 observational ones, reaches primary completion later than 44 of the 103 other live ones, and was the 448th registered.
627 studies on the registry are indexed under Primary Myelofibrosis; 125 are open to participants now.
Browse Primary Myelofibrosis studies →69 of the 453 studies in Primary Myelofibrosis with a site in United States are open now. Recruiting first, the newest first:
John Mascarenhas · Sites in United States
Ages 18+
Takeda · Sites in United States, Argentina, Australia and 28 more countries
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18–75 · Healthy volunteers
Damora Therapeutics · Sites in United States, Australia
Ages 18+
University of Utah · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 101 Primary Myelofibrosis studies recruiting now, 83 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
453 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 166 · Phase 2 219 · Phase 3 45
First in 1992; this study’s year is marked. 17 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 125 across 73 observational studies indexed under Primary Myelofibrosis.
Median enrollment 40 across the 387 interventional studies, 153 across the 35 observational. Of the 328 that completed or were terminated, 152 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
133 of 453 have an industry lead sponsor. The 10 most frequent:
Swedish Orphan Biovitrum is the lead sponsor of 82 studies on the registry; 6 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.
Swedish Orphan Biovitrum has 7 studies filed under Primary Myelofibrosis — fewer than ten, so there is no comparison to draw.
40 of the studies in Primary Myelofibrosis with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06479135Phase 3Kartos Therapeutics, Inc.Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib | 2026-12-31 |
| NCT06468033Phase 3PharmaEssentiaP1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk | 2027-11-18 |
| NCT02934477Center for International Blood and Marrow Transplant ResearchProspective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis | 2026-11 |
| NCT01973881University of Michigan Rogel Cancer CenterQuantitative MRI for Myelofibrosis | 2026-12 |
| NCT06414681University of Kansas Medical CenterCombination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined | 2026-12 |
Add all 40 to your calendar (.ics) → With an account.
Among the 453 studies in Primary Myelofibrosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate real-world treatment patterns and effectiveness of pacritinib, including hematologic and clinical outcomes, and survival through a site-based retrospective chart review of medical records of patients with MF.
This is a multicenter, observational, retrospective chart review study of patients with Myelofibrosis (MF) who received treatment with pacritinib in routine clinical settings with platelet count ≥50 x 109/L at the time of treatment initiation with pacritinib. This study will be conducted entirely through medical chart abstraction; all data will be taken from the patient's medical record, with no additional assessments.
Patients with platelet counts ≥50 x 10\^9/L at pacritinib initiation from a total of 20-25 centers across the US over a 4-year time period (2022 to 2026).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Not Applicable - Observational Study
≥50% spleen length reduction
Time frame: From the Index Date to Week 24 or best response in spleen reduction, assessed up to 49 months.
≥20% spleen length reduction
Time frame: From the Index Date to Week 24 or best response in spleen reduction, assessed up to 49 months.
Change in spleen length
Time frame: Index to Week 24 and at other timepoints, assessed up to 49 months.
Improvement in spleen size category
Time frame: Index to Week 24 and at other timepoints, assessed up to 49 months.
Among those with ≥1 MF-related symptom at index Symptom-specific resolution
Time frame: Index to Week 24 and at other timepoints, assessed up to 49 months.
Among those with ≥1 MF-related symptom at index Decrease in total number of MF-symptoms
Time frame: Index to Week 24 and at other timepoints, assessed up to 49 months.
Among those with ≥1 MF-related symptom at index Change in total number of MF-symptoms
Time frame: Index to Week 24 and at other timepoints, assessed up to 49 months.
Change in blood counts (i.e., white blood cells [WBC], platelets, absolute neutrophil counts, peripheral blast percentage)
Time frame: Index to Week 24 and at other timepoints, assessed up to 49 months.
Among those who are non-transfusion independent (TI) (≥1 RBC transfusion in prior 12 weeks) at index RBC-TI - absence of RBC transfusions over any 12-week period
Time frame: Index to Week 24 and at other timepoints, assessed up to 49 months.
Among those who are non-transfusion independent (TI) (≥1 RBC transfusion in prior 12 weeks) at index ≥50% reduction in number of RBC units transfused
Time frame: Index to Week 12 & Index to Week 24
Among those who are non-transfusion independent (TI) (≥1 RBC transfusion in prior 12 weeks) at index ≥50% reduction in monthly rate of RBC units transfused
Time frame: Index to Week 12 & Index to Week 24
Among those who are non-transfusion independent (TI) (≥1 RBC transfusion in prior 12 weeks) at index change in the number of RBC units transfused
Time frame: Index to Week 24
Among those who are non-transfusion independent (TI) (≥1 RBC transfusion in prior 12 weeks) at index change in the monthly rate of RBC units transfused
Time frame: Index to Week 24
Among those with a platelet count <100 x 109/L at index date Absolute increase in platelet counts ≥30 x 109/L without a platelet transfusion in the prior 2 days
Time frame: Index to best response, assessed up to 49 months.
Among patients with Hb <10 g/dL at index and who are RBC-transfusion dependent (TD) (≥3 RBC units transfused in prior 12 weeks) at index: achieved RBC-TI
Time frame: 12-Week Period with no RBC transfusions administered during the period
Among patients with Hb <10 g/dL at index and who are not RBC-transfusion dependent (TD) (≥3 RBC units transfused in prior 12 weeks) at index: ≥1.5 g/dL increase in average Hb
Time frame: 12-Week Period with no RBC transfusions administered during the period
Among patients who have IWG Hb Minor Response at index and are RBC-TD at index ≥50% reduction in RBC transfusion
Time frame: 12-Week Period without being fully RBC-TI
Among patients who have IWG Hb Minor Response at index and are not RBC-TD at index ≥1 g/dL increase in average Hb
Time frame: 12-Week Period without being fully RBC-TI
Physician-reported progression to leukemia (AML)
Time frame: Index to Follow-up, assessed up to 49 months.
Overall survival
Time frame: Index to Follow-up, assessed up to 49 months.
Leukemia-free Survival
Time frame: Index to Follow-up, assessed up to 49 months.
Type, dose, and number of MF-directed therapies administered
Time frame: At Index (Baseline)
Reasons for treatment switch from a prior MF-directed therapy to pacritinib
Time frame: At Index (Baseline)
Method used to switch from prior JAKi to pacritinib
Time frame: At Index (Baseline)
Physician reported (or Physician confirmed) JAKi withdrawal syndrome after switching to pacritinib from a different JAKi
Time frame: Prior to (index date) and after initiation of pacritinib (up to 49 months).
Pacritinib line of therapy, treatment dose and frequency, changes in dose/and or frequency, frequency of dose changes and reasons for change
Time frame: Prior to (index date) and after initiation of pacritinib (up to 49 months).
Duration of treatment with pacritinib
Time frame: Prior to (index date) and after initiation of pacritinib (up to 49 months).
Concomitant MF-related medications
Time frame: Prior to (index date) and after initiation of pacritinib (up to 49 months).
Reason for discontinuation of pacritinib
Time frame: Prior to (index date) and after initiation of pacritinib (up to 49 months).
Subsequent MF-therapy following discontinuation of pacritinib and time to next Treatment
Time frame: Prior to (index date) and after initiation of pacritinib (up to 49 months).
Demographic characteristics include age, sex, race/ethnicity, geographic region, and insurance type
Time frame: At Index (Baseline)
Body mass index (BMI) for all participants enrolled
Time frame: At Index (Baseline)
Receipt of allo-HSCT among patients referred to allo-HSCT
Time frame: Index to Week 24
Duration of treatment with pacritinib prior to allo-HSCT
Time frame: Index to Week 24
Dose of pacritinib prior to allo-HSCT
Time frame: Index to Week 24
Discontinuation of pacritinib prior to allo-HSCT
Time frame: Index to Week 24
Treatment with pacritinib during conditioning
Time frame: Index to Week 24
Dose of pacritinib during condition
Time frame: Index to Week 24
Duration of treatment with pacritinib after allo-HSCT
Time frame: Index to Week 24
Dose of pacritinib after allo-HSCT
Time frame: Index to Week 24
Type of MF for all participants enrolled
Time frame: At Index (Baseline)
Comorbidities for all participants enrolled
Time frame: At Index (Baseline)
MF Risk Category for all participants enrolled
Time frame: At Index (Baseline)
Bone Marrow Fibrosis Grade for all participants enrolled
Time frame: At Index (Baseline)
Type of MF Mutations for all participants enrolled
Time frame: At Index (Baseline)
Variant Allele Frequency (VAF) for all participants enrolled
Time frame: At Index (Baseline)
Number of Driver Mutations for all participants enrolled
Time frame: At Index (Baseline)
Number of High-Risk Mutations for all participants enrolled
Time frame: At Index (Baseline)
Karyotype for all participants enrolled
Time frame: At Index (Baseline)
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Mar 2027, 6 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: primary completion Jan 2027 → Mar 2027 and completion Jan 2027 → Mar 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.